Adaptive Biotechnologies (ADPT) – Press Releases
-
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
-
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
-
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
-
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
-
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
-
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
-
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
-
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH
-
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
-
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
-
Adaptive Announces Launch of Epic Integration for clonoSEQ®
-
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
-
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
-
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
-
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic C
-
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
-
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
-
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
-
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
-
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
-
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
-
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
-
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
-
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
-
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
-
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
-
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
-
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
-
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
-
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
-
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
-
Capella Space Raises $60M in Growth Equity from the United States Innovative Technology Fund to Expand Satellite Imaging Capacity and Meet Rapidly Growing Customer Demand
-
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
-
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
-
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meetin
-
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meetin
-
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
-
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
-
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
-
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
-
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
-
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
-
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
-
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
-
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
-
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
Back to ADPT Stock Lookup
